Market revenue in 2023 | USD 409.5 million |
Market revenue in 2030 | USD 1,026.8 million |
Growth rate | 14% (CAGR from 2023 to 2030) |
Largest segment | Dna chips |
Fastest growing segment | Lab-on-chip |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Tissue Arrays, Cell Arrays, DNA Chips, Lab-on-chip, Protein Chips |
Key market players worldwide | Agilent Technologies Inc, PerkinElmer, Illumina Inc, Bio-Rad Laboratories Inc, Standard BioTools Inc, GE HealthCare Technologies Inc Common Stock, Thermo Fisher Scientific Inc, Qiagen NV, Randox |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biochip market will help companies and investors design strategic landscapes.
Dna chips was the largest segment with a revenue share of 37.83% in 2024. Horizon Databook has segmented the Japan biochip market based on tissue arrays, cell arrays, dna chips, lab-on-chip, protein chips covering the revenue growth of each sub-segment from 2018 to 2030.
Healthcare and clinical research service providers in Japan have been integrating sequencing technologies for the past couple of years. Ongoing developments in HLA and prenatal NGS testing coupled with international collaborations with American & European companies are expected to fuel the growth of Japan’s biochip market during the forecast period.
Moreover, many hospitals in Japan have started using NGS-based mutational profile screening for patients with solid tumors to direct patients to relevant clinical trials. Various cancer gene panels that are to be used in clinical practice have also been approved by the Ministry of Health, Labour and Welfare of Japan.
However, a medical protocol for reporting and interpreting clinical variants must be developed. Using sequencing technology in this field, significant progress has been made in understanding the molecular causes of cancer. These factors are expected to drive the market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan biochip market, including forecasts for subscribers. This country databook contains high-level insights into Japan biochip market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account